← Database
M&A

LAMEPLAST

Acquired by

TEKNI-PLEX

ITALY Chemicals & Materials EV [1m EUR - 100m EUR] 07/2019

Target

LAMEPLAST

Acquirer

TEKNI-PLEX

Context

Tekni-Plex, Inc. has acquired 100% of the share capital of Lameplast S.p.A. from the Italian private equity firm Aksia Group (Aksia Capital IV fund). This transaction represents the first exit for the Aksia Capital IV fund. Lameplast's expertise in pharmaceutical injection moulding and its strong foothold in the European ophthalmology market will be integrated into Tekni-Plex's global healthcare packaging division. Under Aksia's ownership since 2016, Lameplast had strengthened its management, enhanced R&D, and expanded its commercial presence in the US.

LAMEPLAST, which reported an EBITDA margin of LOGIN in 2018, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 10.2x average currently observed in the Industry & Manufacturing sector.

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Industry & Manufacturing market trends

Target

Lameplast is a leading European manufacturer of primary plastic packaging for the pharmaceutical industry. Based in Italy's "Biomedical Valley," the company specializes in the design and production of single-dose and multi-dose containers using injection and blow moulding technologies. It has a specific leadership position in the ophthalmology, OTC, and cosmetic sectors.

Ent. Value

LOGIN

Equity Value

LOGIN

Multiples Analysis

EV / Revenue

LOGIN

EV / EBITDA

LOGIN

EV / EBIT

LOGIN

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2018
LOGIN
LOGIN
LOGIN
2017
LOGIN
LOGIN
LOGIN

Other operations with LAMEPLAST

mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.